Absolute Antibody expands production to support demand for its recombinant antibodies
Absolute Antibody, an industry-leading provider of recombinant antibody products and services, is expanding its manufacturing facility in northeast England. The increased laboratory space includes a major investment in new automation for Next Generation Sequencing (NGS), expression and purification (HPLC) to enhance recombinant antibody production workflows. The additional space and equipment will enable Absolute Antibody to better service customers and accelerate the expansion of its recombinant antibody portfolio.
“The increased space and automation is a direct result of the continued growth of our company and underlines our commitment to our clients and to advancing recombinant antibody technology,” said Dr Ed Horton, Chief Commercial Officer of Absolute Antibody. “We are excited to leverage our increased production capacity and additional automation capabilities to serve new and existing customers more efficiently and respond to the growing demand for recombinant antibodies across a variety of applications.”
The facility is ISO-certified and located at the Wilton Centre in Redcar, England, where Absolute Antibody has based its research and manufacturing since 2014. The upgraded space includes additional manufacturing lines and state-of-the-art robotics to increase efficiency and enable the completion of larger and higher volume projects. The new labs will also accommodate additional scientific staff members to support company growth.
Absolute Antibody’s facility expansion follows its recent acquisition by LSBio, which provides clients with a larger portfolio of antibody-related products and services. The combined company is focused on increasing the availability of highly defined recombinant antibodies, which offer ensured reproducibility, an animal-free manufacturing process, and the ability to engineer antibodies into any species, isotype or format.